Successful mobilization of peripheral blood stem cells with the DHAP regimen (dexamethasone, cytarabine, cisplatinum) plus granulocyte colony-stimulating factor in patients with relapsed Hodgkin's disease

References

• Josting A, Wolf J, Diehl V. Hodgkin's disease. Prognostic factors and treatment strategies. Curr Opin Oncol 2000;12:403–411.
   Google Scholar
• Linch DC, Winfield D, Goldstone AH et al. Dose intensifica-tion with autologous bone marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial. Lancet 1993;341:1051–1054.
   PubMed Web of Science ®Google Scholar
• Schmitz N, Pfistner B, Sextro M et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for re-lapsed chemosensitive Hodgkin's disease: a randomised trial. Lancet 2002;359:2065–2071.
   PubMed Web of Science ®Google Scholar
• Ferme C, Mounier N, Divine M et al. Intensive salvage therapy with high-dose chemotherapy for patients with advanced Hodgkin's disease in relapse or failure after initial chemotherapy: results of the Groupe d'Etudes des Lym-phomes de l'Adulte H89 Trial. J Clin Oncol 2002;20(2):467–475.
   PubMed Web of Science ®Google Scholar
• Josting A, Katay I, Rueffer U et al. Favorable outcome of patients with relapsed or refractory Hodgkin's disease treated with high-dose chemotherapy and stem cell rescue at the time of maximal response to conventional salvage therapy (Dexa-BEAM). Ann Oncol 1998;9:289–295.
   PubMed Web of Science ®Google Scholar
• Moskowitz CH, Nimer SD, Zelenetz AD et al. A 2-step comprehensive high-dose chemoradiotherapy second-line pro-gram for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model. Blood 2001;97(3):616–623.
   PubMed Web of Science ®Google Scholar
• Jackson GH, Angus B, Carey PJ et al. High dose ifosfamide in combination with etoposide and epirubicin followed by autologous stem cell transplantation in the treatment of relapsed/refractory Hodgkin's disease: a report on toxicity and efficacy. Leuk Lymphoma 2000;37(5-6):561–570.
   PubMed Web of Science ®Google Scholar
• Josting A, Rudolph C, Mapara M et al. Cologne high-dose sequential chemotherapy in relapsed and refractory Hodgkin lymphoma - Results of a large multicenter study for the prospective randomized HDR-2 trial of the German Hodgkin Lymphoma Study Group (GHSG). Ann Oncol 2005;16:116–123.
   PubMed Web of Science ®Google Scholar
• Josting A, Rudolph C, Reiser M et al. Time-intensified dexamethasone/cysplatin/cytarabine: an effective salvage ther-apy with low toxicity in patients with relapsed and refractory Hodgkin's disease. Ann Oncol 2002;13:1628–1635.
   PubMed Web of Science ®Google Scholar
• Josting A, Raemakers JM, Diehl V, Engert A. New concepts for relapsed Hodgkin's disease. Ann Oncol 2002;13\(Suppl. 1):117–121.
   Google Scholar
• Reiser M, Josting A, Draube A et al. Successful peripheral blood stem cell mobilization with etoposide (VP-16) in patients with relapsed or resistant lymphoma who failed cyclophosphamide mobilization. Bone Marrow Transplant 1999;23:1223–1228.
   PubMed Web of Science ®Google Scholar
• Mayer J, Koristek Z, Vasova I et al. Ifosfamide and etoposide-based chemotherapy as salvage and mobilizing regimens for poor prognosis lymphoma. Bone Marrow Transplant 1999;23:413–419.
   PubMed Web of Science ®Google Scholar
• Hertzberg MS, Crombie C, Benson Wet al. Outpatient-based ifosfamide, carboplatin and etoposide (ICE) chemotherapy in transplant-eligible patients with non-Hodgkin's lymphoma and Hodgkin's disease. Ann Oncol 2004;14\(Suppl. 1):il 1–6.
   Google Scholar
• Aurlien E, Holte H, Pharo A et al. Combination chemother-apy with mitoquazon, ifosfamide, MTX, etoposide (MIME) and G-CSF can efficiently mobilize PBSC in patients with Hodgkin's and non-Hodgkins's lymphoma. Bone Marrow Transplant 1998;21:873–878.
   PubMed Web of Science ®Google Scholar
• Magagnoli M, Sarina B, Balzarotti M et al. Mobilizing potential of ifosfamide/vinorelbine-based chemotherapy in pretreated malignant lymphoma. Bone Marrow Transplant 2001;28:923–927.
   PubMed Web of Science ®Google Scholar
• Watts MJ, Ings SJ, Leverett D et al. ESHAP and G-CSF is a superior blood stem cell mobilizing regimen compared to cyclophosphamide 1,5gm - 2 and G-CSF for pretreated lymphoma patients: a matched pairs analysis of 78 patients. Br J Cancer 2000;82(2):278–282.
   PubMed Web of Science ®Google Scholar
• Zinzani PL, Tani M, Molinari AL et al. Ifosfamide, epirubicin and etoposide (IEV) regimen as salvage and mobilizing therapy for relapsed/refractory lymphoma patients. Haemato-logica 2002;87:816–821.
   PubMed Web of Science ®Google Scholar
• Olivieri A, Brunori M, Capelli D et al. Salvage therapy with an outpatient DHAP schedule followed by PBSC transplantation in 79 lymphoma patients: an intention to mobilize and transplant analysis. Eur J Haematol 2004;72:10–17.
   PubMed Web of Science ®Google Scholar
• Tarella C, Castellino C, Cherasco C et al. Peripheral blood progenitor cell mobilization in patients with primary refractory lymphoma or at first relapse: comparison with patients at diagnosis and impact on clinical outcome. Br J Haematol 1997;99:41–46.
   PubMed Web of Science ®Google Scholar
• Baetz T, Belch A, Couban S et al. Gemcitabine dexametha-sone and cisplatin is an active and non-toxic chemotherapy in relapsed or refractory Hodgkin's disease: A phase II study by the National Cancer Institute of Canada Clinical Trials Group. Ann Oncol 2003;14:1762–1767.
   PubMed Web of Science ®Google Scholar